Zumutor Biologics Profile
Key Indicators
- Authorised Capital ₹ 0.13 M
as on 27-06-2024
- Paid Up Capital ₹ 0.12 M
as on 27-06-2024
- Company Age 9 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -9.13%
(FY 2023)
- Profit 2.19%
(FY 2023)
- Ebitda -34.55%
(FY 2023)
- Net Worth 9.42%
(FY 2023)
- Total Assets 11.06%
(FY 2023)
About Zumutor Biologics
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.13 M and a paid-up capital of Rs 0.12 M, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Zumutor Biologics Private Limited India are Anirban Bhattacharya as COMPANY SECRETARY and Kavitha Rodrigues as Ceo. Ashwin Raguraman, Kavitha Rodrigues, and Maloy Ghosh serve as directors at the Company.
- CIN/LLPIN
U73200KA2015FTC081944
- Company No.
081944
- Company Classification
Private Limited Foreign Company Incorporated In India
- Incorporation Date
31 Jul 2015
- Date of AGM
24 Jul 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangalore, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Zumutor Biologics?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anirban Bhattacharya  | Company Secretary | 01-Oct-2016 | Current |
| Kavitha Rodrigues | CEO | 01-Oct-2016 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Maloy Ghosh | Whole-Time Director | 01-Oct-2016 | Current |
| Ashwin Raguraman | Nominee Director | 26-Aug-2021 | Current |
| Kavitha Rodrigues | Director and Ceo | 31-Jul-2015 | Current |
Financial Performance and Corporate Structure Insights of Zumutor Biologics.
Zumutor Biologics Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 9.13% decrease. The company also saw a slight improvement in profitability, with a 2.19% increase in profit. The company's net worth moved up by a moderate rise of 9.42%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Zumutor Biologics?
In 2023, Zumutor Biologics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Human Edge Advisory Services Private LimitedActive 4 years 26 daysAshwin Raguraman is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Zumutor Biologics?
Zumutor Biologics has a workforce of 23 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Zumutor Biologics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Zumutor Biologics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
